Literature DB >> 20208415

Evaluating the role of rheumatoid factors for the development of rheumatoid arthritis in a mouse model with a newly established ELISA system.

Yuki Tanaka1, Hiroaki Komori, Shiro Mori, Yoshiko Soga, Takahito Tsubaki, Miho Terada, Tatsuhiko Miyazaki, Takahiro Fujino, Satoshi Nakamura, Hiroyuki Kanno, Tatsuya Sawasaki, Yaeta Endo, Masato Nose.   

Abstract

Enzyme-linked immunosorbent assays (ELISA) have been widely used to determine quantitatively autoantibodies. However, the processes for the purification and immobilization of antigens in conventional ELISA methods include multiple steps, which have hampered the application for screening of autoantibodies. Here, we have developed a novel ELISA system using the plates pre-coated with glutathione casein to capture recombinant proteins fused to N-terminal glutathione S-transferase (GST). The GST-fused proteins were synthesized with the wheat germ cell-free protein production system. Thus, the present system combined the GST-capture ELISA with the cell-free protein production system, which allowed immobilization of the recombinant proteins with one-step purification. Using this ELISA method, we determined whether rheumatoid factors (RF), which have been considered as one of the representative disease-specific autoantibodies for rheumatoid arthritis (RA), were genetically associated with severity of arthritis in a mouse model for RA, MRL/Mp-lpr/lpr (MRL/lpr). GST-fused human IgG1-Fc (GST-Fc), synthesized with the robotic protein synthesizer, were used as reactants for RF. Serum samples for RF were prepared from 11 lines of a recombinant inbred mouse strain, MXH/lpr, which was established from intercrosses between MRL/lpr and non-arthritic C3H/HeJ-lpr/lpr (C3H/lpr) strains, composed of a different genomic recombination derived from the parental strains in each line. A correlation of RF titers with the severity of the arthritis in these lines was not significant, indicating genetic dissociation of RF from arthritis and that RF is not necessarily required for the development of RA. The present method may provide high-throughput screening for determining the disease-specific autoantibodies in autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20208415     DOI: 10.1620/tjem.220.199

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  6 in total

1.  Visualization of fluid drainage pathways in lymphatic vessels and lymph nodes using a mouse model to test a lymphatic drug delivery system.

Authors:  Tetsuya Kodama; Yuriko Hatakeyama; Shigeki Kato; Shiro Mori
Journal:  Biomed Opt Express       Date:  2014-12-15       Impact factor: 3.732

2.  Imaging of the Mouse Lymphatic Sinus during Early Stage Lymph Node Metastasis Using Intranodal Lymphangiography with X-ray Micro-computed Tomography.

Authors:  Ryo Iwamura; Maya Sakamoto; Shiro Mori; Tetsuya Kodama
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

3.  Optimization of acoustic liposomes for improved in vitro and in vivo stability.

Authors:  Nicolas Sax; Tetsuya Kodama
Journal:  Pharm Res       Date:  2012-09-01       Impact factor: 4.200

4.  Autoantibody Profiles in Collagen Disease Patients with Interstitial Lung Disease (ILD): Antibodies to Major Histocompatibility Complex Class I-Related Chain A (MICA) as Markers of ILD.

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Kiyoe Masuo; Fumiaki Nakajima; Shunichi Funano; Yuki Tanaka; Akiko Komiya; Naoshi Fukui; Tatsuya Sawasaki; Kenji Tadokoro; Masato Nose; Naoyuki Tsuchiya; Shigeto Tohma
Journal:  Biomark Insights       Date:  2015-08-16

5.  A Novel Treatment Method for Lymph Node Metastasis Using a Lymphatic Drug Delivery System with Nano/Microbubbles and Ultrasound.

Authors:  Shigeki Kato; Shiro Mori; Tetsuya Kodama
Journal:  J Cancer       Date:  2015-10-20       Impact factor: 4.207

6.  A model system for studying superselective radiotherapy of lymph node metastasis in mice with swollen lymph nodes.

Authors:  Ryohei Kikuchi; Ariunbuyan Sukhbaatar; Maya Sakamoto; Shiro Mori; Tetsuya Kodama
Journal:  Clin Transl Radiat Oncol       Date:  2019-05-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.